Pharming Group NV and Orchard Therapeutics PLC Announce Collaboration to Develop and Commercialize Ex Vivo Autologous HSC Gene Therapy for Hereditary Angioedema Call Transcript
Welcome, everyone, to today's joint analyst call, Orchard Therapeutics and Pharming Group. My name is Simona, and I will be your coordinator today. (Operator Instructions)
I will now hand you over to your host, Sijmen de Vries, Chief Executive Officer of Pharming Group, to begin. Sijmen, please go ahead.
Thank you very much. Ladies and gentlemen, good afternoon to this joint analyst call. And before I will be saying something, I would like to point out to the next slide, the forward-looking statement slide because we will be making some forward-looking statements about our future plans and development plans, clinical results and other future conditions. And I would like to refer to our website for further information into the SEC statements.
That brings me to introducing my colleagues here today. If everything is correct, you should see some beautiful pictures now of Dr. Anurag Relan, our new Chief Medical Officer; my colleague, Dr. Bobby Gaspar, the CEO of Orchard
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |